ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
|Solubility (25°C)||DMSO ≥ 50 mg/mL|
|Storage||2-8°C, protect from light|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related LPL Receptor Products|
Sonepcizumab (LT 1009) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).
|TC LPA5 4
TC LPA5 4 is a specific non-lipid LPA5 (GPR92) antagonist (IC50=0.8 μM in LPA5-RH7777 cells). Shows selectivity for LPA5 against 80 other screening targets.TC LPA5 4 was shown to inhibit LPA-induced aggregation of isolated human platelets.TC LPA5 4 inhibits proliferation and migration of thyroid cancer cells.
BMS-986278 is a potent LPA1 antagonist with a Kb of 6.9 nM.
The S1P1 agonist SAR247799 is a biased agonist of the S1P1 sphingosine receptor, preferentially activating G protein signaling over the β-arrestin and internalization pathways.
GLPG2938 is a potent and selective S1P2 antagonist.GLPG2938 can be used in the study of idiopathic pulmonary fibrosis (IPF).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.